Phenylketonuria

Slide 1 · Phenylketonuria

Inherited amino acid metabolism and its clinical consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain the PAH–tetrahydrobiopterin system and its metabolic products.

Connect excess phenylalanine and reduced tyrosine to the clinical phenotype.

Distinguish classic PKU, milder hyperphenylalaninemia, and cofactor-related variants.

Interpret neonatal screening and maternal PKU as prevention problems.

Slide 3 · PKU is an inborn error of metabolism

Inherited metabolic disorders disrupt the processing of nutrients and endogenous substrates.

Clinical effects arise from accumulation of a substrate or deficiency of a required product.

Phenylketonuria is a model disorder of amino acid metabolism.

Biochemical pathways provide the link between genotype and phenotype.

Slide 4 · Two ways a metabolic block causes disease

Substrate accumulation

1. Phenylalanine rises when conversion is blocked.

2. Excess substrate or derived metabolites can damage tissue.

Product deficiency

1. Conversion to tyrosine falls.

2. Reduced melanin synthesis explains lighter pigmentation.

Slide 5 · Why neonatal recognition changes outcome

Inherited metabolic defect

Infant initially appears normal

Phenylalanine rises after birth

Early restriction prevents major injury

The screening window precedes overt neurologic damage.

Slide 6 · Classic PKU: The defining lesion

Severe phenylalanine hydroxylase deficiency

Autosomal recessive disease

Inability to convert phenylalanine efficiently into tyrosine

Persistent hyperphenylalaninemia without metabolic control

Slide 7 · A normal newborn examination does not exclude PKU

Birth

Appears clinically normal

First weeks

Plasma phenylalanine increases

By ~6 months

Severe intellectual disability may become evident if untreated

Slide 8 · Phenylalanine has two major fates

Dietary phenylalanine

Incorporation into proteins

Conversion to tyrosine

The PAH system performs the metabolic conversion.

Slide 9 · The normal PAH reaction

Phenylalanine

PAH + BH₄

Tyrosine

Phenylalanine hydroxylase requires the cofactor tetrahydrobiopterin (BH₄).

Slide 10 · Tyrosine is a product of phenylalanine metabolism

Phenylalanine

PAH-mediated hydroxylation

Tyrosine

Melanin synthesis

Reduced tyrosine generation contributes to reduced pigmentation.

Slide 11 · Tetrahydrobiopterin supports PAH activity

BH₄ is a cofactor of the phenylalanine hydroxylase reaction.

PAH protein can be present but function inadequately if a required cofactor is unavailable.

This explains why phenylalanine accumulation is not uniquely caused by PAH-gene mutations.

Slide 12 · The PAH cofactor is recycled

BH₄: Active cofactor

PAH reaction

BH₂: Oxidized form

DHPR-dependent recycling

Simplified cofactor cycle; Enzymatic context adapted conceptually, not reproduced from the textbook figure.

Slide 13 · PAH loss redirects the biochemical pathway

Excess phenylalanine

Minor shunt pathways increase

Tyrosine formation declines

One defect generates metabolite accumulation and relative product deficiency.

Slide 14 · Shunt metabolites enter sweat and urine

Reduced PAH activity

Excess phenylalanine

Greater shunt-pathway flux

Odorous metabolites in urine/sweat

A characteristic “musty” or “mousy” odor is a clinical clue.

Slide 15 · Why pigmentation is reduced

Blocked Phe → Tyr conversion

Less tyrosine available

Reduced melanin formation

Lighter hair and skin

This is a product-deficiency consequence, not the primary neurologic lesion.

Slide 16 · Neurologic injury tracks phenylalanine excess

High phenylalanine concentrations impair developing brain function.

The textbook implicates phenylalanine and/or its metabolites in CNS injury.

The precise contribution of each toxic mechanism is not completely resolved in the source.

Do not present an unproven single neurotoxic pathway as established.

Slide 17 · The developing brain creates an urgent window

Biochemical disturbance

Marked phenylalanine elevation

Developing CNS

Vulnerability during infancy

Untreated outcome

Irreversible neurodevelopmental impairment

Slide 18 · One enzyme defect, several organ-system findings

Biochemical consequence

Clinical expression

Excess phenylalanine / metabolites

Neurodevelopmental injury and neurologic abnormalities

Shunt metabolite production

Characteristic odor of sweat and urine

Reduced tyrosine availability

Lighter hair and skin pigmentation

Slide 19 · PKU is inherited as an autosomal recessive trait

Carrier parent

Carrier parent

Affected child: Pathogenic variants in both PAH alleles

An affected phenotype requires biallelic pathogenic PAH variants.

Slide 20 · Both PAH alleles must be affected

One affected PAH allele generally establishes carrier status rather than classic disease.

Disease emerges when both inherited PAH alleles carry function-impairing variants.

Mutational severity influences the residual enzymatic activity and biochemical phenotype.

Slide 21 · PAH has extensive allelic heterogeneity

Nearly 1,000 PAH mutant alleles described

Different variants can disrupt enzyme function by different degrees.

The same clinical diagnostic category is genetically heterogeneous.

Molecular confirmation follows biochemical phenotyping.

Slide 22 · Residual PAH activity determines severity

Severely reduced activity

Classic PKU: Marked phenylalanine elevation

Less severe activity loss

Milder forms of hyperphenylalaninemia

Modest elevation only

May lack classic neurologic manifestations

Slide 23 · Classic PKU sits at the severe end of the spectrum

Severe PAH deficiency causes prominent elevation of circulating phenylalanine.

Without treatment, neurodevelopment is seriously impaired.

Biochemical severity cannot be inferred solely from the presence of a positive screening test.

Slide 24 · Milder PAH deficiency is biologically distinct

Severe functional loss

1. Large rise in phenylalanine

2. Risk of untreated classic neurologic phenotype

Partial activity retained

1. Smaller rise in phenylalanine

2. Clinical consequences vary with biochemical severity

Slide 25 · Benign hyperphenylalaninemia is not classic PKU

Some PAH variants cause modest elevations of phenylalanine.

Individuals may screen positive without developing classic neurologic manifestations.

Phenylalanine measurement is needed to distinguish biochemical phenotypes.

Slide 26 · A screening result is not a severity classification

Newborn screen abnormal

Measure blood phenylalanine

Establish biochemical degree

Classify and investigate the cause

“Screen positive” is a prompt for assessment—not a complete diagnosis.

Slide 27 · Population frequency varies by ancestry

Approximately 1 in 10,000 live births of Northern European descent

Textbook figure for inherited PKU variants, not a universal global estimate.

Classic PKU is described as more frequent among persons of Scandinavian descent.

Frequency differs among populations; Do not generalize one ancestry-specific value.

Slide 28 · Untreated PKU evolves after birth

At delivery

Typically no obvious signs

Weeks

Phenylalanine progressively elevated

Months

Neurologic and other clinical features emerge

Slide 29 · Intellectual disability is the critical preventable outcome

Severe intellectual disability becomes evident early in untreated classic PKU.

The injury is described as irreversible once established.

The opportunity is prevention before the neurologic phenotype develops.

Slide 30 · Severe intellectual outcomes were common untreated

Fewer than 4% had IQ >50–60

Historical untreated cohort description.

It illustrates disease severity without screening and metabolic therapy.

It is not an estimate for infants treated in modern screening programs.

Slide 31 · Speech and mobility may be profoundly affected

~1/3

Never walk

~2/3

Cannot talk

Textbook-reported features of untreated affected children; Historical clinical severity, not treated prognosis.

Slide 32 · Seizures are part of the neurologic phenotype

Seizures may accompany intellectual disability in untreated disease.

Additional neurologic abnormalities can be present.

These features reflect CNS involvement but are not specific to PKU.

Slide 33 · Pigmentary findings have a biochemical explanation

Observed feature

1. Hair and skin may be less pigmented.

2. This accompanies rather than defines PKU.

Metabolic rationale

1. PAH blockade reduces tyrosine formation.

2. Tyrosine is a melanin precursor.

Slide 34 · Eczema and odor support clinical suspicion

Eczema is a recognized accompanying manifestation of untreated classic PKU.

A musty or mousy body-fluid odor reflects increased shunt metabolites.

Neither sign can replace the biochemical assessment of phenylalanine.

Slide 35 · Clinical recognition is too late for optimal prevention

Symptom-based detection

1. Findings appear after accumulating metabolic exposure.

2. Neurodevelopmental impairment may already be irreversible.

Neonatal screening

1. Detects biochemical abnormalities earlier.

2. Allows timely dietary intervention.

Slide 36 · Why biochemical newborn screening is appropriate

Infants are typically normal on examination at birth.

The relevant metabolite can be measured.

Early dietary correction can prevent serious neurologic injury.

This sequence creates a rationale for universal neonatal screening.

Slide 37 · Screening targets the biochemical phenotype

Elevated blood phenylalanine

The finding identifies hyperphenylalaninemia.

It does not by itself specify PAH genotype or cofactor mechanism.

Further evaluation determines severity and etiology.

Slide 38 · Biochemical diagnosis precedes molecular assignment

Abnormal newborn screening

Measure plasma/serum phenylalanine

Characterize hyperphenylalaninemia

Identify disease-causing variant when indicated

Phenylalanine quantification as necessary for differentiation.

Slide 39 · Classic PKU produces marked phenylalanine elevation

The textbook characterizes levels in classic PKU as typically ≥5-fold normal.

Milder elevations can occur with less severe PAH variants.

No fixed concentration-based diagnostic cutoff is supplied in the excerpt.

Avoid inventing absolute thresholds or current treatment targets.

Slide 40 · Genotyping answers a different question

Biochemical testing

Molecular testing

Demonstrates actual phenylalanine elevation

Identifies disease-causing PAH variants

Helps assess phenotype severity

Establishes familial variant information

Essential for distinguishing mild from classic disease

Enables targeted carrier testing in relatives

Slide 41 · Carrier testing follows identification of the variant

Biochemical diagnosis

PAH genotype characterized

Familial variant known

Targeted carrier testing

A family-specific molecular result makes targeted genetic counseling more informative.

Slide 42 · Not all PKU-like biochemistry is due to PAH

~98%

PAH mutations

~2%

BH₄ synthesis/recycling abnormalities

Approximate etiologic proportions reported; Cofactor disorders require distinct evaluation.

Slide 43 · Cofactor defects block an otherwise normal enzyme system

PAH gene defect

1. PAH protein has insufficient activity.

2. Hyperphenylalaninemia reflects enzymatic deficiency.

BH₄ pathway defect

1. Required cofactor is deficient or inadequately recycled.

2. PAH reaction is functionally impaired.

Slide 44 · DHPR supports BH₄ regeneration

BH₂

DHPR

BH₄

Regenerating the cofactor permits continued PAH-dependent phenylalanine conversion.

Slide 45 · Cause matters because management differs

PAH-deficient classic PKU

BH₄-pathway variants

Primary defect: phenylalanine hydroxylase

Primary defect: BH₄ synthesis or recycling

Dietary phenylalanine restriction is central

Dietary restriction alone is not sufficient for the variant syndrome

Some adult approaches also target the system

Sapropterin is described as effective for relevant variants

Slide 46 · Dietary phenylalanine restriction targets the substrate

Reduced dietary phenylalanine input

Lower circulating phenylalanine

Less biochemical neurotoxicity

Protection of neurodevelopment

Intervention changes substrate availability, not the inherited PAH genotype.

Slide 47 · Restriction is not metabolic elimination

Phenylalanine remains an amino acid required for protein synthesis.

The dietary strategy is controlled restriction of intake, not absolute removal.

The source emphasizes early institution of dietary control; No dietary prescription is given.

Slide 48 · Treatment timing determines preventability

Before significant injury

1. Early screening and restriction

2. Neurodevelopmental injury can be avoided

After injury is established

1. Metabolic control remains relevant

2. Established severe neurodevelopmental injury is not reversed by delayed diagnosis

Slide 49 · The causal chain can be interrupted

PAH deficiency

Inherited and persistent

Phenylalanine elevation

Modifiable by dietary therapy

Neurologic injury

Preventable with early intervention

Slide 50 · Additional treatment mechanisms act at different points

Approach

Conceptual target

Dietary phenylalanine restriction

Reduces substrate input

BH₄ (sapropterin) therapy

Supports cofactor-responsive PAH activity

Phenylalanine ammonia-lyase (PAL)

Alternative route for excess phenylalanine disposal

Slide 51 · Sapropterin is a synthetic BH₄ preparation

The BH₄ cofactor is required for phenylalanine hydroxylation.

The source describes sapropterin treatment for cofactor-related forms.

This does not mean every genotype is equally responsive.

Slide 52 · Phenylalanine ammonia-lyase offers an alternative route

Excess phenylalanine

PAL enzyme substitution

Alternative metabolism of phenylalanine

Lower substrate burden

PAL among adult treatment options.

Slide 53 · Variant diagnosis prevents a treatment mismatch

A newborn has hyperphenylalaninemia. Genetic evaluation does not identify pathogenic PAH variants sufficient to explain the biochemical phenotype.

Which system must also be considered?

Teaching answer: BH₄ synthesis or recycling defects; The excerpt emphasizes that dietary restriction alone is not adequate for these variants.

Slide 54 · Maternal PKU is a distinct fetal exposure problem

High maternal phenylalanine can be teratogenic

Many successfully treated girls with PKU reach reproductive age.

Hyperphenylalaninemia may recur if dietary treatment is discontinued.

The fetus is exposed to maternal metabolites across the placenta.

Slide 55 · Maternal metabolites can cross the placenta

Maternal circulation

Elevated phenylalanine

Fetal tissues

Developmental exposure

PL

AC

EN

TA

Phenylalanine exposure

Maternal metabolic control determines fetal exposure even when the fetus does not have biallelic PAH deficiency.

Slide 56 · Maternal PKU is not fetal classic PKU

Maternal PKU

1. Affected mother has elevated phenylalanine.

2. Fetal injury results from transplacental exposure.

Classic PKU in infant

1. Infant has biallelic PAH-related enzyme deficiency.

2. Postnatal hyperphenylalaninemia damages brain unless treated.

Slide 57 · Fetal risk includes microcephaly and neurodevelopmental injury

Children exposed to poorly controlled maternal PKU may have intellectual disability.

Microcephaly is a characteristic reported developmental consequence.

The mechanism is teratogenic exposure during development, not necessarily affected fetal genotype.

Slide 58 · Congenital heart disease is part of maternal PKU

Congenital heart defects are reported among affected offspring.

They reflect fetal exposure during organ development.

The association is part of the maternal metabolic phenotype rather than a diagnostic marker of neonatal classic PKU.

Slide 59 · Robbins quantifies risks in uncontrolled maternal PKU

75–90%

Intellectual disability and microcephaly

15%

Congenital heart disease

Textbook-reported estimates for offspring of women with elevated phenylalanine; Do not extrapolate to well-controlled pregnancies.

Slide 60 · Fetal severity correlates with maternal phenylalanine

Lower controlled maternal exposure

Lower teratogenic burden

Higher maternal phenylalanine

Greater likelihood and severity of anomalies

Exposure during development

Can affect several fetal organs

Slide 61 · A carrier fetus can still be affected by maternal PKU

Mother has PKU

Maternal phenylalanine high

Placental transfer to fetus

Developmental injury despite carrier fetal genotype

This is metabolic teratogenesis, not direct fetal expression of classic recessive PKU.

Slide 62 · Preventive care starts before conception

Preconception

Establish phenylalanine restriction

Throughout gestation

Maintain maternal metabolic control

After delivery

Continue appropriate long-term disease management

Slide 63 · Maternal treatment prevents an exposure, not a genotype

Not modifiable

1. Maternal PAH genotype

2. Inherited recurrence risk

Modifiable

1. Maternal circulating phenylalanine

2. Transplacental fetal metabolic exposure

Slide 64 · Case: A well-looking newborn with abnormal screening

A newborn appears normal on examination. Routine biochemical screening shows hyperphenylalaninemia.

Why is urgent biochemical follow-up necessary?

Teaching answer: PKU typically lacks obvious findings at birth; Early phenylalanine control can avert later irreversible CNS injury.

Slide 65 · Case: Interpreting mild hyperphenylalaninemia

An asymptomatic infant has a reproducibly modest phenylalanine elevation rather than a markedly elevated concentration.

What does a positive screening test not establish?

Teaching answer: It does not establish classic severe PKU; Benign or milder hyperphenylalaninemia requires biochemical distinction.

Slide 66 · Case: Future pregnancy in a patient with PKU

An adult with known PKU stopped dietary therapy years earlier and now plans pregnancy.

What preventive intervention is emphasized?

Teaching answer: Restart maternal phenylalanine restriction before conception and maintain it through pregnancy.

Slide 67 · Four diagnostic distinctions to retain

Question

Most relevant distinction

Does the infant look normal?

Normal appearance does not exclude PKU.

Is phenylalanine elevated?

This defines the biochemical screening signal.

How severe is the elevation?

Separates classic from milder hyperphenylalaninemia.

What is the defect?

PAH vs BH₄-pathway etiology informs treatment.

Slide 68 · Concept synthesis: Phenotype follows metabolic flux

PAH system fails

Phenylalanine and shunt metabolites ↑

Tyrosine formation ↓

Neurologic injury, musty odor, and hypopigmentation are mechanistically connected.

Slide 69 · Phenylketonuria: Final clinical principles

Classic PKU is biallelic PAH deficiency with marked hyperphenylalaninemia.

The infant may be asymptomatic at birth despite a preventable future brain injury.

Measure phenylalanine, establish severity, and evaluate PAH/BH₄ mechanisms.

Maternal metabolic control must begin before conception to reduce fetal injury.

Slide 70 · Primary reading

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 10, “Phenylketonuria,” printed pp. 422–423.

Conceptual PAH and BH₄ schematic based on discussion associated with Fig. 10.14; all diagrams in this deck are original editable shapes.